EpimAb Biotherapeutics,  a clinical stage biotech company specializing in bispecific antibodies, announced today that the company will present and share a clinical progress update at the J.P. Morgan 39th Annual Healthcare Conference .

“Targeted cancer therapies concomitantly addressing the cMet and EGFR pathways via a bispecific molecule have gained considerable momentum in 2020. EpimAb is one of just a handful of biopharmaceutical companies pushing a proprietary cMet/EGFR therapeutic antibody program through the clinical trials,” said Dr. Chengbin Wu, CEO and Founder of EpimAb. “We are pleased to begin 2021 with our first presentation at the J.P. Morgan Healthcare Conference and look forward to making further progress with our clinical and development bispecific antibody programs.”

Presentation details are as follows:
Date: Monday, January 11, 2021
Time: 12:10 PM ET
Virtual access:https://bit.ly/2Xiwytf

EpimAb is creating a pipeline of novel proprietary bispecific antibody therapeutics with a focus on oncology and other areas of high value to patients. EMB-01, EpimAb’s lead candidate designed to simultaneously target EGFR and cMET on tumor cells, is currently progressing through a Phase I/II clinical study in both China and the U.S. EMB-02, EpimAb’s second therapeutic development candidate, which simultaneously targets two checkpoint proteins, PD-1 and LAG-3, and has shown strong anti-tumor activities in preclinical models resistant to standard anti-PD-1 monotherapies, received FDA clearance last year to progress into the clinic in the U.S. EpimAb’s third candidate, EMB-06, is a differentiated T cell engaging bispecific targeting CD3 and BCMA.